Voya Investment Management LLC Raises Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Voya Investment Management LLC increased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 8.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,043 shares of the medical instruments supplier's stock after acquiring an additional 3,522 shares during the quarter. Voya Investment Management LLC owned approximately 0.20% of LeMaitre Vascular worth $4,150,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LMAT. Price T Rowe Associates Inc. MD lifted its position in shares of LeMaitre Vascular by 0.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock worth $26,240,000 after purchasing an additional 1,680 shares during the period. Massar Capital Management LP purchased a new stake in LeMaitre Vascular during the fourth quarter worth $284,000. Hsbc Holdings PLC boosted its position in LeMaitre Vascular by 43.5% during the 4th quarter. Hsbc Holdings PLC now owns 3,861 shares of the medical instruments supplier's stock valued at $358,000 after acquiring an additional 1,170 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of LeMaitre Vascular by 319.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,646 shares of the medical instruments supplier's stock worth $428,000 after acquiring an additional 3,538 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in shares of LeMaitre Vascular by 5.9% during the 4th quarter. MetLife Investment Management LLC now owns 12,434 shares of the medical instruments supplier's stock worth $1,146,000 after purchasing an additional 695 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price for the company. Finally, Lake Street Capital lifted their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular has an average rating of "Moderate Buy" and an average target price of $98.14.

Insider Buying and Selling at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.79% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Stock Down 0.3 %

Shares of NASDAQ:LMAT traded down $0.24 during trading on Wednesday, hitting $81.85. The stock had a trading volume of 49,912 shares, compared to its average volume of 161,934. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of 44.72, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86. The stock has a 50-day simple moving average of $84.77 and a two-hundred day simple moving average of $93.23.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company's revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.44 earnings per share. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, May 15th. LeMaitre Vascular's dividend payout ratio is currently 40.40%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.